Therapeutic Focus

Thanks to a deep expertise in drug discovery and development, Pharmaleads has designed, patented and is currently developing compounds from two first-in-class chemical families of Dual ENKephalinase 1 Inhibitors (DENKIs) 2.

Pharmaleads’ DENKIs: Painkillers armed with a completely new mode of action to tackle severe pain.

These innovative compounds, PL37 and PL265, show a high potential in the treatment of severe pain. They both act by enhancing the local concentrations of enkephalins, eliciting a “physiological” analgesia devoid of the side-effects of exogenous opiates, such as morphine.

  1. 1. Enkephalinases are the enzymes that rapidly inactivate endogenous opioids (our body’ “natural” analgesics)
  2. 2. See article in Nature Reviews Drug Discovery by Pharmaleads’ scientists: Roques BP, Fournié-Zaluski MC, Wurm M Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain. NRDD 2012 Apr; 11(4):292-310

Read next

Discover our publications
Press & media coverage
Contact & find us

Pharmaleads SA
11, rue Watt
75013 Paris

Tel: +33 (0)1 44 06 70 00
Fax: +33 (0)1 44 06 60 99
info@pharmaleads.com

Get the access map